Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ubidecarenone - Berg Pharma

Drug Profile

Ubidecarenone - Berg Pharma

Alternative Names: API-31510; BP 31510; BPM-31510; C-31510; c31510; Coenzyme Q10 - Cytotech; Coenzyme Q10 injectable nanosuspension; CoQ10 - Cytotech; Ubiquinone injectable nanosuspension

Latest Information Update: 22 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytotech Labs
  • Developer Berg Pharma; National Cancer Institute (USA); Stanford Cancer Institute; Stanford University; University of Miami
  • Class Antihyperlipidaemics; Antineoplastics; Benzoquinones; Cardiotonics; Cardiovascular therapies; Coenzymes; Small molecules
  • Mechanism of Action Antioxidants; Apoptosis stimulants; Electron transport chain complex protein modulators; Proto-oncogene protein c-bcl-2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa; Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma; Pancreatic cancer; Squamous cell cancer
  • Phase I/II Glioma
  • Phase I Epidermolysis bullosa
  • No development reported Solid tumours
  • Discontinued Basal cell cancer; Leukaemia; Lung cancer; Wounds

Most Recent Events

  • 18 Jan 2024 Updated efficacy data from a phase-II trial in Pancreatic cancer released by Berg Pharma
  • 14 Nov 2023 Ubidecarenone phase I development in Epidermolysis-bullosa is ongoing in USA (BPG Bio website; November 2023)
  • 14 Nov 2023 BPGbio plans a phase IIb trial for Sacropenia (IV) (BPGbio website, November 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top